Cargando…

Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial

INTRODUCTION: Sepsis is a life-threatening organ disorder caused by a dysregulated inflammatory response to infection with no effective treatment options exist thus far. Therefore, novel therapeutic methods are urgently advocated for decreasing the high mortality rate. Recently, preclinical studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chunxue, Zhao, Dongyang, Zheng, Liang, Bao, Xiaowei, Yang, Qian, Jiang, Sen, Zhou, Xiaohui, Tang, Lunxian, Liu, Zhongmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981327/
https://www.ncbi.nlm.nih.gov/pubmed/35379638
http://dx.doi.org/10.1136/bmjopen-2021-058444
_version_ 1784681580788187136
author Wang, Chunxue
Zhao, Dongyang
Zheng, Liang
Bao, Xiaowei
Yang, Qian
Jiang, Sen
Zhou, Xiaohui
Tang, Lunxian
Liu, Zhongmin
author_facet Wang, Chunxue
Zhao, Dongyang
Zheng, Liang
Bao, Xiaowei
Yang, Qian
Jiang, Sen
Zhou, Xiaohui
Tang, Lunxian
Liu, Zhongmin
author_sort Wang, Chunxue
collection PubMed
description INTRODUCTION: Sepsis is a life-threatening organ disorder caused by a dysregulated inflammatory response to infection with no effective treatment options exist thus far. Therefore, novel therapeutic methods are urgently advocated for decreasing the high mortality rate. Recently, preclinical studies supported the efficacy of mesenchymal stem cells (MSCs) in the treatment of sepsis. In this study, we aim to test the safety, tolerability and efficacy of human umbilical cord MSCs (HUC-MSCs) for the treatment of pneumonia induced sepsis. METHODS AND ANALYSIS: This study is a single-centre, randomised single-blind parallel group, placebo-controlled trial. Forty eligible participants with pneumonia-induced sepsis will be randomly assigned to the observational cohort and the interventional cohort in a 1:1 ratio. In addition to the standard treatments recommended by the Sepsis 3.0 guidelines, HUC-MSCs will be administered intravenously as adjunctive therapy on day 0 at a dose of 1×10(6) cells/kg with a total volume of 100 mL diluted with normal saline through 120 mL/hour intravenous central line infusion in the interventional cohort. Placebo (normal saline) will also be administered through 120 mL/hour intravenous central line infusion at the same quantity (total volume of 100 mL) in the observational cohort. The study is approved by Research Ethics Board of East Hospital/Tongji University, which has been registered on Chinese clinical trial registry (chictr.org.cn) and initiated from October 2021. All the participants will be followed at regular intervals for 1 year. Funding is from the ‘National Natural Science Foundation, China and top‐level clinical discipline project of Shanghai Pudong’. This study is the first trial to assess the safety and efficacy of HUC-MSCs for the treatment of sepsis induced by pneumonia. The results will advance our understanding of the mode of action of HUC-MSCs and will also be critical for the design of future investigation in larger randomised controlled trials in multicentre. These data will offer insight into defining endpoints, key biomarkers and sample size determination. ETHICS AND DISSEMINATION: This study has been approved by the Research Ethics Board of East Hospital, Tongji University (Shanghai, China), which has accepted responsibility for supervising all aspects of the study (DFSC-2021(CR-04). The results of this study will be presented at both national and international conferences and be considered for publication in a peer-reviewed scientific journal. All the results presented in this study will be of group data, therefore, individual participants will not be identifiable. TRIAL REGISTRATION NUMBER: ChiCTR2100050544, the trial is now at the stage of pre-results.
format Online
Article
Text
id pubmed-8981327
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89813272022-04-22 Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial Wang, Chunxue Zhao, Dongyang Zheng, Liang Bao, Xiaowei Yang, Qian Jiang, Sen Zhou, Xiaohui Tang, Lunxian Liu, Zhongmin BMJ Open Emergency Medicine INTRODUCTION: Sepsis is a life-threatening organ disorder caused by a dysregulated inflammatory response to infection with no effective treatment options exist thus far. Therefore, novel therapeutic methods are urgently advocated for decreasing the high mortality rate. Recently, preclinical studies supported the efficacy of mesenchymal stem cells (MSCs) in the treatment of sepsis. In this study, we aim to test the safety, tolerability and efficacy of human umbilical cord MSCs (HUC-MSCs) for the treatment of pneumonia induced sepsis. METHODS AND ANALYSIS: This study is a single-centre, randomised single-blind parallel group, placebo-controlled trial. Forty eligible participants with pneumonia-induced sepsis will be randomly assigned to the observational cohort and the interventional cohort in a 1:1 ratio. In addition to the standard treatments recommended by the Sepsis 3.0 guidelines, HUC-MSCs will be administered intravenously as adjunctive therapy on day 0 at a dose of 1×10(6) cells/kg with a total volume of 100 mL diluted with normal saline through 120 mL/hour intravenous central line infusion in the interventional cohort. Placebo (normal saline) will also be administered through 120 mL/hour intravenous central line infusion at the same quantity (total volume of 100 mL) in the observational cohort. The study is approved by Research Ethics Board of East Hospital/Tongji University, which has been registered on Chinese clinical trial registry (chictr.org.cn) and initiated from October 2021. All the participants will be followed at regular intervals for 1 year. Funding is from the ‘National Natural Science Foundation, China and top‐level clinical discipline project of Shanghai Pudong’. This study is the first trial to assess the safety and efficacy of HUC-MSCs for the treatment of sepsis induced by pneumonia. The results will advance our understanding of the mode of action of HUC-MSCs and will also be critical for the design of future investigation in larger randomised controlled trials in multicentre. These data will offer insight into defining endpoints, key biomarkers and sample size determination. ETHICS AND DISSEMINATION: This study has been approved by the Research Ethics Board of East Hospital, Tongji University (Shanghai, China), which has accepted responsibility for supervising all aspects of the study (DFSC-2021(CR-04). The results of this study will be presented at both national and international conferences and be considered for publication in a peer-reviewed scientific journal. All the results presented in this study will be of group data, therefore, individual participants will not be identifiable. TRIAL REGISTRATION NUMBER: ChiCTR2100050544, the trial is now at the stage of pre-results. BMJ Publishing Group 2022-04-03 /pmc/articles/PMC8981327/ /pubmed/35379638 http://dx.doi.org/10.1136/bmjopen-2021-058444 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Emergency Medicine
Wang, Chunxue
Zhao, Dongyang
Zheng, Liang
Bao, Xiaowei
Yang, Qian
Jiang, Sen
Zhou, Xiaohui
Tang, Lunxian
Liu, Zhongmin
Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial
title Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial
title_full Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial
title_fullStr Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial
title_full_unstemmed Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial
title_short Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial
title_sort safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial
topic Emergency Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981327/
https://www.ncbi.nlm.nih.gov/pubmed/35379638
http://dx.doi.org/10.1136/bmjopen-2021-058444
work_keys_str_mv AT wangchunxue safetyandefficacyofhumanumbilicalcordmesenchymalstemcellsforthetreatmentofsepsisinducedbypneumoniastudyprotocolforasinglecentrerandomisedsingleblindparallelgrouptrial
AT zhaodongyang safetyandefficacyofhumanumbilicalcordmesenchymalstemcellsforthetreatmentofsepsisinducedbypneumoniastudyprotocolforasinglecentrerandomisedsingleblindparallelgrouptrial
AT zhengliang safetyandefficacyofhumanumbilicalcordmesenchymalstemcellsforthetreatmentofsepsisinducedbypneumoniastudyprotocolforasinglecentrerandomisedsingleblindparallelgrouptrial
AT baoxiaowei safetyandefficacyofhumanumbilicalcordmesenchymalstemcellsforthetreatmentofsepsisinducedbypneumoniastudyprotocolforasinglecentrerandomisedsingleblindparallelgrouptrial
AT yangqian safetyandefficacyofhumanumbilicalcordmesenchymalstemcellsforthetreatmentofsepsisinducedbypneumoniastudyprotocolforasinglecentrerandomisedsingleblindparallelgrouptrial
AT jiangsen safetyandefficacyofhumanumbilicalcordmesenchymalstemcellsforthetreatmentofsepsisinducedbypneumoniastudyprotocolforasinglecentrerandomisedsingleblindparallelgrouptrial
AT zhouxiaohui safetyandefficacyofhumanumbilicalcordmesenchymalstemcellsforthetreatmentofsepsisinducedbypneumoniastudyprotocolforasinglecentrerandomisedsingleblindparallelgrouptrial
AT tanglunxian safetyandefficacyofhumanumbilicalcordmesenchymalstemcellsforthetreatmentofsepsisinducedbypneumoniastudyprotocolforasinglecentrerandomisedsingleblindparallelgrouptrial
AT liuzhongmin safetyandefficacyofhumanumbilicalcordmesenchymalstemcellsforthetreatmentofsepsisinducedbypneumoniastudyprotocolforasinglecentrerandomisedsingleblindparallelgrouptrial